Roxithromycin is an oral macrolide antibiotic agent that has been repeatedly reported to provoke excessive prolongation of the Q-T interval and torsades de pointes in clinical settings. To investigate the mechanisms underlying the arrhythmogenic side effects of roxithromycin, we studied the molecular mechanisms of roxithromycin on human ether-à-go-go-related gene (hERG) K(+) channels expressed in human embryonic kidney (HEK293) cells. Roxithromycin was found to inhibit wild-type (WT) hERG currents in a concentration-dependent manner with a half-maximum block concentration (IC50) of 55.8 ± 9.1 μmol/L. S6 residue hERG mutants (Y652A and F656C) showed reduced levels of hERG current blockage attributable to roxithromycin. Roxithromycin also inhibited the trafficking of hERG protein to the cell membrane, as confirmed by Western blot analysis and confocal microscopy. These findings indicate that roxithromycin may cause acquired long-QT syndrome via direct inhibition of hERG current and by disruption of hERG protein trafficking. Mutations in drug-binding sites (Y652A or F656C) of the hERG channel were found to attenuate hERG current blockage by roxithromycin, but did not significantly alter the disruption of trafficking.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1139/cjpp-2012-0456 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
In vitro safety evaluation of dopamine D3R antagonist, R-VK4-116, as a potential medication for the treatment of opioid use disorder.
PLoS One
December 2024
Therapeutic Development Branch, Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institute of Health, Rockville, Maryland, United States of America.
R-VK4-116 is currently being developed as a medication to treat opioid use disorder (OUD). To characterize in vitro safety properties of R-VK4-116, metabolic stability in hepatocytes or liver microsomes, metabolite identification, metabolism/transporter-mediated drug interactions, lysosomal perturbation, mitochondrial toxicity, off-target enzyme effects, cellular and nuclear receptor functional assays, electrophysiological assays, CiPA, KINOMEscanTM, plasma protein binding, phospholipidosis and steatosis assays were performed. Overall, R-VK4-116 was metabolically stable in hepatocytes and microsomes.
View Article and Find Full Text PDFChelerythrine triggers the prolongation of QT interval and induces cardiotoxicity by promoting the degradation of hERG channels.
J Biol Chem
November 2024
Department of Pharmacology, College of Pharmacy, Harbin Medical University, Harbin, Heilongjiang Province, China. Electronic address:
Article Synopsis
- Cardiotoxicity during drug treatment is a significant concern, especially regarding the role of cardiac hERG channels in the heart's action potential repolarization.
- Chelerythrine shows promise as an anti-cancer agent but its safety profile, particularly concerning cardiac effects, is not well understood.
- This study finds that Chelerythrine can prolong the QT interval and action potential duration, potentially increasing the risk of cardiac toxicity through enhanced degradation of hERG channels via ubiquitination and lysosomal pathways under hypoxic conditions.
Stereoselective block of the hERG potassium channel by the Class Ia antiarrhythmic drug disopyramide.
Cell Mol Life Sci
November 2024
School of Physiology, Pharmacology and Neuroscience, Biomedical Sciences Building, University of Bristol, University Walk, Bristol, BS8 1TD, UK.
Article Synopsis
- Potassium channels from the human hERG gene are affected by various drugs, and this study specifically investigates the effects of chiral disopyramide, a Class Ia antiarrhythmic, on hERG currents in HEK 293 cells.* -
- The findings show that the S(+) enantiomer of disopyramide is more potent at inhibiting hERG current compared to the R(-) form, with IC values of 3.9 µM and 12.9 µM respectively, and certain mutations in hERG alter these effects.* -
- Molecular simulations indicate that the S(+) form binds more effectively to specific residues in the hERG channel, while the R(-)
Discovery and evaluation of HW161023 as a potent and orally active AAK1 inhibitor.
Bioorg Med Chem Lett
December 2024
Humanwell Pharmaceuticals US Inc., 421 Sovereign Court, Ballwin, MO 63011, USA.
AAK1, also known as AP2-associated protein kinase 1, is an enzyme that belongs to the family of serine/threonine protein kinases. It regulates the assembly and disassembly of clathrin-coated pits and thereby protein endocytosis, by phosphorylating the μ2 subunit of the AP2 complex, which is a key component of clathrin-coated vesicles. LX9211 is currently the only selective small molecule AAK1 inhibitor at the clinical trial stage for diabetic peripheral neuropathic pain, which was found to be safe and well tolerated in healthy participants in phase I clinical trials.
View Article and Find Full Text PDFLeukotriene B4 is elevated in diabetes and promotes ventricular arrhythmogenesis in guinea pig.
J Cell Physiol
October 2024
Nora Eccles Harrison Cardiovascular Research and Training Institute (CVRTI), University of Utah School of Medicine, Salt Lake City, Utah, USA.
Article Synopsis
- Diabetes patients have a higher risk (~50%) of sudden cardiac death primarily due to ventricular arrhythmias, with the proinflammatory lipid mediator leukotriene B4 (LTB4) playing a significant role.
- In studies using guinea pig hearts, it was found that elevated LTB4 in diabetic models leads to harmful heart rhythms and decreases critical potassium current, affecting heart function.
- The research indicates that targeting LTB4 receptors could be a promising therapeutic strategy to improve heart health and reduce the risk of sudden cardiac death in diabetes patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!